The intermediate-activity L597V BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway

Genes and Development

Volumn 26, Issue 17, 2012, Pages 1945-1958

  Andreadi, Catherine ^a   Cheung, Lai Kay ^a   Giblett, Susan ^a   Patel, Bipin ^a   Jin, Hong ^a   Mercer, Kathryn ^a   Kamata, Tamihiro ^a   Lee, Pearl ^a   Williams, Alexander ^b   McMahon, Martin ^c   Marais, Richard ^d,e   Pritchard, Catrin ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

BRAF; Cancer; ERK signaling pathway; Oncogene; RASopathies

Indexed keywords

B RAF KINASE; MUTANT PROTEIN; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; FACE DYSMORPHIA; FIBROBLAST; GENE ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC EPISTASIS; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; EPISTASIS, GENETIC; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCK-IN TECHNIQUES; HUMANS; LUNG; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; PROTEIN ARRAY ANALYSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RAF KINASES; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 3;

EID: 84865843828     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.193458.112     Document Type: Article

References (50)

1. Anastasaki C, Estep AL, Marais R, Rauen KA, Patton EE. 2009. Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet 18: 2543-2554.
2. Ashworth A, Lord CJ, Reis-Filho JS. 2011. Genetic interactions in cancer progression and treatment. Cell 145: 30-38.
3. Basso AD, Kirschmeier P, Bishop WR. 2006. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47: 15-31.
4. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA. 2007. Genetic progression and the waiting time to cancer. PLoS Comput Biol 3: e225. doi: 10.1371/journal.pcbi.0030225.
5. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57: 289-300.
6. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J, Baccarini M, Barbacid M. 2011. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19: 652-663.
7. Brady SC, Coleman ML, Munro J, Feller SM, Morrice NA, Olson MF. 2009. Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Cancer Res 69: 6773-6781.
8. Champion KJ, Bunag C, Estep AL, Jones JR, Bolt CH, Rogers RC, Rauen KA, Everman DB. 2011. Germline mutation in BRAF codon 600 is compatible with human development: De novo p.V600G mutation identified in a patient with CFC syndrome. Clin Genet 79: 468-474.
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
10. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379-384.
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
12. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, Bastian BC, Springer C, Marais R. 2006. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66: 9483-9491.
13. Ehrenreiter K, Kern F, Velamoor V, Meissl K, Galabova-Kovacs G, Sibilia M, Baccarini M. 2009. Raf-1 addiction in Rasinduced skin carcinogenesis. Cancer Cell 16: 149-160.
14. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, et al. 2008. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
15. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. 2004. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5: R80. doi: 10.1186/gb-2004-5-10-r80
16. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, et al. 2010. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435.
17. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, et al. 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221.
18. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R, Pritchard C. 2001. MEK kinase activity is not necessary for Raf-1 function. EMBO J 20: 1940-1951.
19. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248.
20. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, et al. 2007. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 67: 4933-4939.
21. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. 2010. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
22. Kamata T, Hussain J, Giblett S, Hayward R, Marais R, Pritchard C. 2010. BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res 70: 8475-8486.
23. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, et al. 2004. B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292-6298.
24. Karreth FA, Frese KK, Denicola GM, Baccarini M, Tuveson DA. 2011. C-Raf is required for the initiation of lung cancer by K-Ras. Cancer Discov 1: 128-136.
25. Kerr KM. 2001. Pulmonary preinvasive neoplasia. J Clin Pathol 54: 257-271.
26. Keyse SM. 2008. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27: 253-261.
27. Kim HJ, Bar-Sagi D. 2004. Modulation of signalling by Sprouty: A developing story. Nat Rev Mol Cell Biol 5: 441-450.
28. Malumbres M, Barbacid M. 2003. RAS oncogenes: The first 30 years. Nat Rev Cancer 3: 459-465.
29. March HN, Rust AG, Wright NA, Ten Hoeve J, de Ridder J, Eldridge M, van der Weyden L, Berns A, Gadiot J, Uren A, et al. 2011. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 43: 1202-1209.
30. Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M, Marais R, Pritchard C. 2005. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65: 11493-11500.
31. Montagut C, Settleman J. 2009. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134.
32. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. 2010. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
33. Niault T, Sobczak I, Meissl K, Weitsman G, Piazzolla D, Maurer G, Kern F, Ehrenreiter K, Hamerl M, Moarefi I, et al. 2009. From autoinhibition to inhibition in trans: The Raf-1 regulatory domain inhibits Rok-α kinase activity. J Cell Biol 187: 335-342.
34. Noble C, Mercer K, Hussain J, Carragher L, Giblett S, Hayward R, Patterson C, Marais R, Pritchard CA. 2008. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell 31: 862-872.
35. Packer LM, East P, Reis-Filho JS, Marais R. 2009. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res 22: 785-798
36. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22: 153-183.
37. Pierpont EI, Pierpont ME, Mendelsohn NJ, Roberts AE, Tworog-Dube E, Rauen KA, Seidenberg MS. 2010. Effects of germline mutations in the Ras/MAPK signaling pathway on adaptive behavior: Cardiofaciocutaneous syndrome and Noonan syndrome. Am J Med Genet A 152A: 591-600.
38. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
39. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. 2009. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci 106: 4519-4524.
40. Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, et al. 2011. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet 157: 136-146.
41. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. 2006. Germline mutations in genes within the MAPK pathway cause cardiofacio-cutaneous syndrome. Science 311: 1287-1290.
42. Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, et al. 2009. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum. Hum Mutat 30: 695-702.
43. Schuhmacher AJ, Guerra C, Sauzeau V, Canamero M, Bustelo XR, Barbacid M. 2008. A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 118: 2169-2179.
44. Schwenk F, Baron U, Rajewsky K. 1995. A cretransgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23: 5080-5081.
45. Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, et al. 2007. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 21: 694-707.
46. Smyth GK. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3. doi: 10.2202/1544-6115.1027.
47. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, et al. 2012. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366: 207-215.
48. Tidyman WE, Rauen KA. 2009. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19: 230-236.
49. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, et al. 2004. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5: 375-387.
50. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, et al. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.